Jacobus Pharmaceutical Co. Inc.

Agency continuing policy, despite loss in court, failure to persuade Congress

Congress to pass FDA bills in lame duck, noisy gridlock expected in 2023

House passes user fee reauthorization, Senate committee delays action 

Federal court ruling that orphan exclusivity covers an entire disease puts kids at risk, FDA officials say

Plus Terran gains rights to two late-stage candidates from Sanofi, and updates from Ampio, Nephris, Jacobus and more

BioCentury’s editors also discuss the implications of Catalyst’s win over FDA in court and the latest in translation

A federal appeals court ruled FDA’s attempt to thwart high price for old drug violates Orphan Drug Act

Genesis and Genentech collaborate to identify drug candidates using AIStanford spinout and AI platform company Genesis Therapeutics Inc. entered into a collaboration agreement with the

Ironwood to downsize after Phase III GERD failureIronwood Pharmaceuticals Inc. (NASDAQ:IRWD) said it plans to discontinue development of IW-3718 after the therapy missed the primary endpoint in a

Pharma execs call out Belcher's price hikes as 'misuse' of Orphan designation